Covid shows drugmakers needtocollaboratein R&D;'
We were the first company to launch favipiravir in the Indian market and knew this would invite ample competition, says Glenn Saldanha, chairman & MD, Glenmark11-08-2020
11-08-2020
Glenmark to launch higher strength Favipiravir to reduce pill-burden to patients
Drugmaker Glenmark Pharmaceuticals is set to introduce antiviral favipiravir at a higher strength (400 mg), for the treatment of mild to moderate Covi06-08-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark introduces higher strength (400 mg) of FabiFlu(r) to reduce pill burden of COVID-19 treatment06-08-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, August 17, 2020 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.05-08-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, August 14, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2020 to August 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2020.05-08-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2020
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2020 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2020 to August 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2020.05-08-2020
Sun Pharma launches cheapest favipiravir brand in India, at Rs 35 a pill
Pricing pressure in this category is already visible as Glenmark revised its original price (Rs 103 per tablet) to Rs 79 per tablet within a month of the launch04-08-2020
Stock query: Glenmark on medium-term uptrend
Company has the potential to trend up and test a long-term resistance at 50002-08-2020
Stock calls by Nilesh Jain of Anand Rathi: Buy Glenmark Pharma, Tata Elxsi
Glenmark's stock has reclaimed its short term 21-DMA31-07-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
Sub:- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - S&P; Global Ratings With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P; Global Ratings for your reference. Request you to kindly take the same on record.29-07-2020